Cargando…

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil

Chronic thromboembolic pulmonary hypertension (CTEPH) is successfully treatable with pulmonary endarterectomy (PEA), balloon pulmonary angioplasty, and medical therapy. Registry to Evaluate Early and Long‐Term Pulmonary Arterial Hypertension Disease Management risk score (RRS) is able to predict lon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jansa, Pavel, Kopeć, Grzegorz, Torbicki, Adam, Sadushi‐Kolici, Roela, Campean, Ioana‐Alexandra, Halank, Michael, Simkova, Iveta, Steringer‐Mascherbauer, Regina, Salobir, Barbara, Klepetko, Walter, Lindner, Jaroslav, Lang, Irene M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440840/ https://www.ncbi.nlm.nih.gov/pubmed/37609358 http://dx.doi.org/10.1002/pul2.12274

Ejemplares similares

Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2018)

Intravenous Treprostinil in Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension Using Implantable Pumps—Single-Center Experience over More Than a Decade
por: Steringer-Mascherbauer, Regina, et al.
Publicado: (2023)

Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy
por: Skoro-Sajer, Nika, et al.
Publicado: (2014)

Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension—procedural safety and system-related complications
por: Steringer-Mascherbauer, Regina, et al.
Publicado: (2020)

Patient Satisfaction with a Dedicated Infusion Pump for Subcutaneous Treprostinil to Treat Pulmonary Arterial Hypertension
por: Waligóra, Marcin, et al.
Publicado: (2023)

Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
por: Moser, Bernhard, et al.
Publicado: (2014)

Neutrophil extracellular traps and monocyte subsets at the culprit lesion site of myocardial infarction patients
por: Mangold, Andreas, et al.
Publicado: (2019)

Central versus Peripheral CTEPH—Clinical and Hemodynamic Specifications
por: Kaldararova, Monika, et al.
Publicado: (2022)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
por: McSweeney, Julia, et al.
Publicado: (2023)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
por: Chapman, Richard W., et al.
Publicado: (2021)

Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina
por: Lescano, Adrián, et al.
Publicado: (2022)

Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction: Study protocol for a randomized controlled trial
por: Mascherbauer, Julia, et al.
Publicado: (2016)

Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension
por: Swisher, John W., et al.
Publicado: (2016)

Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases
por: Kavgacı, Akif, et al.
Publicado: (2023)

Cannabidiol (CBD) for the treatment of subcutaneous treprostinil (Remodulin(®)) site pain: a case report
por: Brewer, Jacqueline, et al.
Publicado: (2023)

An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
por: Kurzyna, Marcin, et al.
Publicado: (2017)

Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells
por: Lambers, Christopher, et al.
Publicado: (2018)

Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation
por: Lambers, Christopher, et al.
Publicado: (2018)

Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry
por: Guth, Stefan, et al.
Publicado: (2021)

Treprostinil for pulmonary hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2008)

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension
por: Raina, Amresh, et al.
Publicado: (2013)

An Event-driven Trial for Oral Treprostinil. Progress but Not the Holy Grail
por: Hill, Nicholas S., et al.
Publicado: (2020)

Pediatric subcutaneous treprostinil site maintenance and pain control strategies from the Pediatric Pulmonary Hypertension Network
por: Jackson, Emma O., et al.
Publicado: (2021)

Case report: Stepwise transition from subcutaneous treprostinil to epoprostenol in high-risk pulmonary arterial hypertension
por: Mori, Ana Laura, et al.
Publicado: (2021)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
por: Kingrey, John F., et al.
Publicado: (2023)

Inhaled treprostinil: a therapeutic review
por: Channick, Richard N, et al.
Publicado: (2012)

Inhaled treprostinil and pulmonary arterial hypertension
por: Nadler, Samuel T, et al.
Publicado: (2010)

Treprostinil stimulates the engraftment of haematopoetic stem cells
por: Hussain, Filza, et al.
Publicado: (2011)

Successful management of an inadvertent excessive treprostinil overdose
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2013)

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
por: Richter, Manuel J., et al.
Publicado: (2020)

Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1): A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study
por: Bonderman, Diana, et al.
Publicado: (2014)

Atrial fibrillation and atrial tachycardia in patients with chronic thromboembolic pulmonary hypertension treated with pulmonary endarterectomy
por: Havranek, Stepan, et al.
Publicado: (2020)

The pathophysiology of chronic thromboembolic pulmonary hypertension
por: Simonneau, Gérald, et al.
Publicado: (2017)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022)

Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation
por: Kazemi, Zahra, et al.
Publicado: (2016)

The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD
por: Kolb, Martin, et al.
Publicado: (2022)

Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic
por: Jansa, Pavel, et al.
Publicado: (2022)

Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy
por: Adachi, Shiro, et al.
Publicado: (2022)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Dosing characteristics of oral treprostinil in real-world clinical practice
por: Balasubramanian, Vijay P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4uffu99gmfmhcta9tkvevqp7hd